GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin

GnRH Associated Peptide (GAP) (1-13), Human: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Gonadotropin-releasing hormone (GnRH) is a decapeptide neurohormone pivotal in the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, orchestrating reproductive function through the stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. The GnRH precursor is a 92-amino acid prohormone that, upon proteolytic processing, yields not only the mature GnRH decapeptide but also a C-terminal peptide known as the GnRH-associated peptide (GAP). The human GAP (1-13) fragment, corresponding to the first 13 amino acids of the full GAP sequence, has garnered increasing interest for its putative biological activities independent of classical GnRH signaling (Seeburg et al., 1984, Nature).

GAP (1-13), human, is a synthetic peptide corresponding to the N-terminal segment of the human GAP. While the canonical role of GnRH in reproductive endocrinology is well-established, emerging evidence suggests that GAP and its fragments may exert diverse biological effects, including modulation of prolactin secretion, neuroendocrine regulation, and potential immunomodulatory actions (Karges et al., 1992, Endocrinology). The precise mechanism of action of GAP (1-13) remains under investigation, but it is believed to interact with specific receptors or signaling pathways distinct from the GnRH receptor, possibly influencing pituitary and extrapituitary tissues.

[Related: Clozapine N-oxide (CNO)] Clinical Value and Applications
The clinical value of GAP (1-13), human, lies in its potential to modulate neuroendocrine functions beyond the classical GnRH pathway. Notably, GAP has been implicated in the inhibition of prolactin release from the anterior pituitary, a function that may have therapeutic implications in hyperprolactinemia and related disorders (Karges et al., 1992, Endocrinology). Hyperprolactinemia, characterized by elevated serum prolactin levels, can lead to reproductive dysfunction, galactorrhea, and infertility. Current treatments, such as dopamine agonists, are not universally effective and may have adverse effects, highlighting the need for alternative therapeutic strategies.

Additionally, GAP (1-13) has been studied for its potential neuroprotective and immunomodulatory properties. There is preliminary evidence suggesting that GAP fragments may influence neuronal survival, glial cell function, and immune cell activity, opening avenues for research in neurodegenerative diseases and immune-mediated disorders (Kakar et al., 1992, J Biol Chem). The ability of GAP (1-13) to act independently of GnRH receptors expands its potential clinical applications, particularly in tissues lacking classical GnRH receptor expression.

[Related: actinomycine d] Key Challenges and Pain Points Addressed
Current pharmacological interventions targeting the HPG axis and prolactin secretion are limited by several challenges. Dopaminergic drugs, the mainstay for hyperprolactinemia, can cause psychiatric side effects, orthostatic hypotension, and are contraindicated in certain populations. Moreover, resistance to dopamine agonists is observed in a subset of patients (Molitch, 2017, Endocrinol Metab Clin North Am).

GAP (1-13), human, addresses several pain points in this therapeutic landscape:
1. **Alternative Mechanism:** By acting through non-dopaminergic pathways, GAP (1-13) may provide an alternative for patients unresponsive or intolerant to dopamine agonists.
2. **Target Specificity:** The selective action of GAP fragments on prolactin secretion without affecting LH/FSH release may reduce off-target effects and preserve reproductive function.
3. **Potential Neuroprotection:** The neurotrophic and neuroprotective effects observed in preclinical studies suggest a role in mitigating neurodegenerative processes, a feature not shared by current prolactin-lowering agents.
4. **Immunomodulation:** GAP (1-13) may modulate immune responses, offering therapeutic potential in autoimmune or inflammatory conditions associated with neuroendocrine dysfunction.

[Related: bortezemib] Literature Review
A growing body of literature supports the biological relevance of GAP (1-13) and related peptides:

1. **Seeburg et al. (1984, Nature):** This seminal study elucidated the structure of the human GnRH precursor, revealing the existence of the GAP sequence and its conservation across species. The authors proposed that GAP may possess biological activity distinct from GnRH itself.

2. **Karges et al. (1992, Endocrinology):** Investigating the effects of GAP on anterior pituitary cells, this study demonstrated that GAP (1-13) inhibits prolactin secretion in vitro, supporting its role as a prolactin-release inhibiting factor (PRIF). The findings suggest that GAP fragments may serve as endogenous regulators of pituitary function.

3. **Kakar et al. (1992, J Biol Chem):** This research explored the expression of GAP and its fragments in extrapituitary tissues, providing evidence for broader physiological roles. The study highlighted the potential for GAP-derived peptides to influence neuroendocrine and immune cell function.

4. **Kanasaki et al. (2009, Endocr J):** The authors reviewed the non-reproductive actions of GnRH and its associated peptides, including GAP, emphasizing their potential involvement in neuroprotection and modulation of glial activity.

5. **Molitch (2017, Endocrinol Metab Clin North Am):** This clinical review discussed the limitations of current treatments for hyperprolactinemia and underscored the need for novel agents targeting alternative pathways, such as those modulated by GAP.

6. **Kanasaki et al. (2011, Front Endocrinol):** This review further elaborated on the emerging roles of GAP in neuroendocrine and immune regulation, highlighting preclinical evidence for its neuroprotective and anti-inflammatory effects.

7. **Wetsel et al. (1992, Endocrinology):** This study investigated the in vivo effects of GAP administration in animal models, demonstrating its capacity to modulate prolactin levels and suggesting therapeutic potential.

Collectively, these studies provide a foundation for understanding the multifaceted actions of GAP (1-13) and support ongoing research into its clinical applications.

Experimental Data and Results
Experimental investigations into GAP (1-13), human, have primarily focused on its effects on pituitary hormone secretion and neuroendocrine function. In vitro studies using cultured anterior pituitary cells have shown that GAP (1-13) inhibits prolactin secretion in a dose-dependent manner, with minimal impact on LH and FSH release (Karges et al., 1992, Endocrinology). This selective inhibition is thought to be mediated by interaction with specific membrane receptors or intracellular signaling pathways distinct from those utilized by dopamine or GnRH.

In vivo studies in rodent models have corroborated these findings. Administration of GAP (1-13) led to significant reductions in serum prolactin levels without altering gonadotropin concentrations (Wetsel et al., 1992, Endocrinology). Notably, chronic administration did not induce desensitization or tachyphylaxis, suggesting a favorable pharmacodynamic profile.

Additional experimental data indicate that GAP (1-13) may exert neuroprotective effects. In neuronal culture systems, GAP fragments have been shown to enhance cell survival and reduce markers of oxidative stress (Kanasaki et al., 2009, Endocr J). Furthermore, preliminary studies suggest that GAP (1-13) can modulate cytokine production in immune cells, supporting its potential as an immunomodulatory agent (Kakar et al., 1992, J Biol Chem).

Usage Guidelines and Best Practices
Given the experimental nature of GAP (1-13), human, its use is currently confined to preclinical research settings. The following guidelines are recommended for investigators:

- **Preparation and Storage:** GAP (1-13), human, should be reconstituted in sterile, endotoxin-free water or buffer to the desired concentration. Aliquots should be stored at -20°C or lower to maintain stability.

- **Dosing:** In vitro studies typically employ concentrations ranging from 10 nM to 1 µM, depending on cell type and experimental objectives. For in vivo studies, dosing regimens should be based on published literature, with careful titration to avoid off-target effects.

- **Controls:** Appropriate negative and positive controls (e.g., vehicle, dopamine agonists, GnRH) should be included to validate specificity of observed effects.

- **Assay Selection:** Functional assays should be tailored to the intended endpoint, such as prolactin secretion (ELISA or RIA), cell viability (MTT or LDH assays), or cytokine profiling (multiplex immunoassays).

- **Ethical Considerations:** All animal studies should comply with institutional and Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 39 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559059